Skip to main content

Biosyent Inc(RX-X)
TSX Venture

Today's Change
Delayed Last Update

Closing Bell: Biosyent Inc flat on Wednesday (RX)

Automated Summaries - The Globe and Mail - Wed Apr 17, 4:02PM CDT

Biosyent Inc opened trading today at $8.53 and closed at $8.55. prices ranged from $8.50 to $8.55.

Share prices $verbed percentage_change% from the previous day's close of $8.55.

During the day across North America, the TSX Composite closed -0.45% at 21642.87, the S&P 500 closed -0.21% at 5051.41, the Dow Jones Industrial Average closed 0.17% at 37798.97 and the Nasdaq Composite closed -0.12% at 15865.25.

Biosyent Inc has listed on the Toronto Venture Exchange (TSX-V) under the ticker RX.

A total of 4,750 shares was traded during the last trading day, with total trades of 15. On average, Biosyent Inc has traded 2,678 shares in the last five days and 5,287 year-to-date.

The TSX-V market on the whole today saw 2,131 price advancers against 3,083 declines and 114 unchanged.

During the prior 52 weeks, RX.VN has traded as high as $9.26 (December 29,2023) and low as $7.03 (July 06,2023). Moreover, the shares have advanced 11.04 percent in the last 12 months, while they have decreased -7.27% this year.

It announced a 0.04 dividend on February 07/24, with an February 28/24 ex-date and March 15/24 pay day.

Following today's trading, Biosyent Inc has a market capitalization of $99.26 million on a float of 11,610 shares outstanding. Its annual EPS is $0.53.

Biosyent Inc is a TSX Drug Specialty & Generic company headquartered in Mississauga, CAN.

Based on 1.00 analysts, Biosyent Inc gets an average recommendation of "Moderate Buy" according to Zacks. Currently, there are 1 buy ratings for the stock.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe

inside the market
Short sales on the TSX: What bearish investors are betting against
Larry MacDonald